Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial

IMPORTANCE: Proliferative verrucous leukoplakia (PVL) is an aggressive oral precancerous disease characterized by a high risk of transformation to invasive oral squamous cell carcinoma (OSCC), and no therapies have been shown to affect its natural history. A recent study of the PVL immune landscape...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Glenn J., Villa, Alessandro, Nandi, Shuvro P., Shi, Ruichao, ONeill, Anne, Liu, Mofei, Quinn, Charles T., Treister, Nathaniel S., Sroussi, Herve Y., Vacharotayangul, Piamkamon, Goguen, Laura A., Annino, Donald J., Rettig, Eleni M., Jo, Vickie Y., Wong, Kristine S., Lizotte, Patrick, Paweletz, Cloud P., Uppaluri, Ravindra, Haddad, Robert I., Cohen, Ezra E. W., Alexandrov, Ludmil B., William, William N., Lippman, Scott M., Woo, Sook-bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654930/
https://www.ncbi.nlm.nih.gov/pubmed/37971722
http://dx.doi.org/10.1001/jamaoncol.2023.4853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654930/
https://www.ncbi.nlm.nih.gov/pubmed/37971722
http://dx.doi.org/10.1001/jamaoncol.2023.4853

Ejemplares similares